Chromosome 17P-linked prostate cancer susceptibility gene

Details Chromosome 17P-linked prostate cancer susceptibility gene Chromosome 17P-linked prostate cancer susceptibility gene

2005-01-18

2005-01-18

Harris, Alana M. (Department: 1642)

Chemistry: molecular biology and microbiology

Animal cell, per se ; composition thereof; process of...

C435S069100, C435S070100, C435S320100, C536S023100, C536S023500

Reexamination Certificate

active

06844189

ABSTRACT:
The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human prostate cancer predisposing gene (HPC2), some alleles of which cause susceptibility to cancer, in particular prostate cancer. More specifically, the present invention relates to germline mutations in the HPC2 gene and their use in the diagnosis of predisposition to prostate cancer. The invention also relates to presymptomatic therapy of individuals who carry deleterious alleles of the HPC2 gene. The invention further relates to somatic mutations in the HPC2 gene in human prostate cancer and their use in the diagnosis and prognosis of human prostate cancer. Additionally, the invention relates to somatic mutations in the HPC2 gene in other human cancers and their use in the diagnosis and prognosis of human cancers. The invention also relates to the therapy of human cancers which have a mutation in the HPC2 gene, (including gene therapy, protein replacement therapy, protein mimetics, and inhibitors). The invention further relates to the screening of drugs for cancer therapy. Finally, the invention relates to the screening of the HPC2 gene for mutations, which are useful for diagnosing the predisposition to prostate cancer.

REFERENCES:
patent: 5925519 (1999-07-01), Jensen et al.
Verma, et al, Nature, 1997, vol. 389, pp. 239-242.*
Eck, et al, Gene-Based Therapy, In: The Pharmacological Basis of Therapeutics, Goodman and Gilman, Ed.s, 1996, pp. 77-101.*
New England Biolabs (1993/1994 Catalog.*
Ohagi et al., Identification and analysis of teh gene encoding human PC2, a prohormone convertase expressed in neuroendocrine tissues, PNAS, vol. 89, pp. 4977-4981, Jun. 1992.*
Bowie et al., Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions, Science, vol. 247, pp. 1306-1310, Mar. 1990.*
Burgess et al., Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from It's Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue, The Journal of Cell, Nov. 1990.*
Lazar et al., Transforming Growth Factor alpha: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities, Molecular and Cellular Biology, pp. 1247-1252, Mar. 1988.*
Bork, Powers and Pitfalls in Sequence Analysis: The 70% Hurdle, Genome Research, pp. 398-400, 2000.*
Cooney, K.A. et al. (1997). “Prostate Cancer Susceptibility Locus on Chromosome 1q: a Confirmatory Study,”J. Natl. Can. Inst.89:955-959.
Cooney, K.A. et al. (1998). “Hereditary Prostate Cancer in African-American Families,”Seminars Urologic Oncol.16:202-206.
Xu, J. et al. (1998). “Evidence for a prostate cancer susceptibility locus on the X chromosome,”Nature Genet.20:175-179.
Database Gencore on EST, No. AC005277, Birren et al., “Homo sapienschromosome 17, clone hRPK.597_M_12, complete sequence,” Gene Sequence, Jul. 23, 1998.
Database Gencore on EST, No. N36229,Hillier et al., “yy30c04.sl Soares melanocyte 2NbHMHomo sapienscDNA clone,” Gene Sequence, Jul. 16, 1996.
X. Gao, et al., “Loss of Heterozygosity of theBRCA1and Other Loci on Chromosone 17q in Human Prostate Cancer,” Cancer Research, vol. 55, Mar. 1, 1995, pp. 1002-1005.
C. W. Rinker-Schaeffer, et al., “Differential Suppression of Mammary and Prostate Cancer Metastasis by Human Chromosomes 17 and 111,” Cancer Research, vol. 54, Dec. 1, 1994, pp. 6249-6259.
S. V. Tavtigian, “A candidate prostate cancer susceptibility gene at chromosome 17p,” Nature Genetics, vol. 27, Feb. 2001, pp. 172-180.

Affiliated with

Also associated with

Rating

Chromosome 17P-linked prostate cancer susceptibility gene does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Chromosome 17P-linked prostate cancer susceptibility gene, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chromosome 17P-linked prostate cancer susceptibility gene will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3415954